STAT+: Scholar Rock wins FDA approval for first drug to target SMA muscle loss
A late-stage clinical trial found that, when combined with an SMN2-targeting drug, Isembyld caused young patients’ motor skills to improve after a year.
Story detail
Read the key details here, then continue on the original publisher.
A late-stage clinical trial found that, when combined with an SMN2-targeting drug, Isembyld caused young patients’ motor skills to improve after a year.
Join our channel to receive the latest headlines and breaking stories as soon as they are published.
Comments (0)
Join the conversation. Comments are rate-limited, secured, and GDPR-compliant.
No comments yet. Be the first to share your thoughts!